India launched two government-backed biotech facilities to scale alternative protein production, investing $4.5 million in a BioFoundry Centre and opening an incubation hub that has already supported 26 startups.
India is betting that government-built infrastructure — not venture capital — is the fastest way to close the country's massive protein gap, and in doing so, it's pioneering a model of state-led biotech development that challenges the assumption alternative proteins are a Western investment story. In October 2024, the Indian government opened two new biotech facilities aimed at scaling alternative protein production, making the country one of the most aggressive state backers of the sector globally. The twin launches form the operational backbone of India's BioE3 policy, announced by the Department of Biotechnology in August 2024, which commits to building biomanufacturing capacity across the country with a focus on high-value biomolecules, bioenergy, and smart proteins.
The common assumption about government investment in alternative proteins is that it's largely a Western phenomenon, concentrated in Singapore, Israel, and parts of Europe. India's moves complicate that picture. With a protein market already valued at $1.5 billion and the Indian Council of Medical Research estimating that roughly 70% of the country's adult population is protein-deficient, India has both the scale and the nutritional urgency to justify serious public spending in this space. But what makes the Indian approach distinct isn't just the spending — it's the strategy of embedding scale-up infrastructure directly within public research institutions rather than relying on private sector manufacturing partnerships that have failed startups elsewhere.
The first facility is a BioFoundry Centre at the Indian Institute of Science Education and Research (IISER) in Mohali, Punjab, backed by ₹42 crore (approximately $5 million) in funding from the Department of Biotechnology over two years. It's designed to bridge the gap between lab research and commercial production, housing 10,000-liter fermenters, downstream processing systems, and high-throughput experimental platforms — the exact kind of mid-scale infrastructure that biotech startups globally have struggled to access. The second is the BIRAC-BioNest Incubation Centre at the CSIR-Central Food Technological Research Institute (CFTRI) campus in Mysore, which is now operational and supports food tech startups working in precision fermentation, CRISPR-based crop improvement, and nutraceuticals. According to BIRAC's 2024 annual report, BioNest has supported over 50 startups to date, which have collectively filed more than 30 patents and contributed to over 100 peer-reviewed research publications.
India's Science and Technology Minister Jitendra Singh, speaking at the Mohali inauguration in October, framed the rationale in terms of national food security: "With rising demand for protein and growing environmental concerns, alternative protein options have become imperative." He described the facilities as critical to developing what the government calls "smart proteins" — products developed through synthetic biology, microbial fermentation, and plant biotechnology — arguing they "can offer a scalable and sustainable pathway for the future of food" in a country where traditional animal agriculture cannot keep pace with demand.
Consumer demand appears to back the investment. A January 2025 NielsenIQ survey found that 37% of Indian citizens want to add more plant proteins to their diet. Major foodservice brands are responding accordingly: Starbucks India rolled out cold foams in late 2024 featuring yeast-derived protein from Indian startup SuperYou, McDonald's India has introduced McPlant-adjacent vegetarian protein products across several metro markets, and Hilton Hotels ran plant protein menu initiatives across its Indian locations throughout 2024. This corporate uptake signals that the demand side of the equation is already moving — the bottleneck, as it has been globally, is production capacity.
That manufacturing gap remains the real test of India's infrastructure-first bet. As we've previously covered, fermentation startups around the world have struggled to find manufacturing partners even after raising significant capital. India's government-backed approach, which embeds scale-up infrastructure directly within public research institutions, could offer a fundamentally different model — one where the state provides the mid-scale manufacturing that the private sector has failed to build. Whether ₹42 crore for Mohali and comparable commitments for Mysore are enough to meaningfully close the production gap for an entire national sector is a fair question, but the strategic intent is unmistakable: India wants to build the pipes, not just fund the ideas. If the model works, it could become a template for other protein-deficient nations looking to leapfrog the venture-backed approach that has stalled in the West.
